Astrazeneca Plc ADR (AZN)

$184.32 -4.09 (-2.17%)
Market Cap 287.76B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 20.26
Forward PE 18.07
Profit Margin 13.01%
Debt to Equity Ratio 0.67
Volume 2,659,600
Avg Vol 6,758,452
Day's Range N/A - N/A
Shares Out 3.10B
Stochastic %K 92%
Beta 0.34
Analysts Strong Sell
Price Target $99.83

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modi...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Fax: 44 1223 352 858
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
Quantumup
Quantumup Feb. 3 at 7:23 PM
BofA⬆️ $BBIO's PT to $88 from $85 and reiterated at a Buy after providing its thoughts ahead of 4Q earnings. $ALNY $PFE NVO $AZN - IONS $BAYRY Here's what BofA had to say in its note: https://x.com/Quantumup1/status/2018766232087130238?s=20
0 · Reply
TalkMarkets
TalkMarkets Feb. 3 at 5:34 PM
The #FTSE100 Finish Line - Tuesday, Feb. 3 $EWU $AZN https://talkmarkets.com/content/global-markets/the-ftse-100-finish-line-tuesday-feb-3?post=554705
0 · Reply
Auphiliate
Auphiliate Feb. 3 at 4:29 PM
$AUPH Also added $AZN to my watchlist! 🤷‍♀️
0 · Reply
Chipwars
Chipwars Feb. 3 at 2:39 PM
$AZN NYSE-listed AstraZeneca scored a winning debut on the NYSE during Monday's session, climbing 0.7%. The firm began trading on the exchange, marking the largest company transfer by market capitalization in NYSE history. https://finance.yahoo.com/news/nyse-content-advisory-pre-market-135500825.html
0 · Reply
Chipwars
Chipwars Feb. 3 at 1:45 PM
$AZN This is excellent news. A priority review means that the drug WORKS, for breast cancer, and is rushed through to stop people dying. Great news for those patients as well as for Astrazeneca stock. https://in.investing.com/news/company-news/fda-grants-priority-review-to-astrazenecas-breast-cancer-drug-datroway-93CH-5218086
0 · Reply
IndependentIntelInt
IndependentIntelInt Feb. 3 at 1:21 PM
$EOSE $AZN Clean and pharma
0 · Reply
briefingcom
briefingcom Feb. 3 at 1:16 PM
$AZN: AstraZeneca updates on U.S. regulatory review of Saphnelo subcutaneous formulation https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260203051146AZN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
Chipwars
Chipwars Feb. 3 at 11:22 AM
$AZN https://finance.yahoo.com/news/astrazeneca-plc-nasdaq-azn-announces-093429467.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAALU3JVjKj7DzNa5xvaKMAewwX7VbIHPv_UieB1kq1zKD17BLIwkmM18QDhH7dpt3T5btYP9xcp2lO-q9KVk7eBpbD8yxnNa9_EXA_j4CGYUUKwWK3mCfVAw2kqmLWjhKUilZNxkFu8Olbb-Uqc2-ba9UjfQUdliWNxchDZJoR8hY
0 · Reply
Pevzner_Maestro
Pevzner_Maestro Feb. 3 at 9:13 AM
$AZN I’m thinking of entering short
1 · Reply
chazthespaz
chazthespaz Feb. 3 at 5:50 AM
$NVAX yall see $AZN astra zeneca? Maybe theres some synergy there. Maybe we will spike to $100 by next week 🤷
0 · Reply
Latest News on AZN
AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA

Feb 3, 2026, 2:42 AM EST - 19 hours ago

AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA

US FDA rejects AstraZeneca's easier-to-use version of lupus therapy

Feb 3, 2026, 2:18 AM EST - 20 hours ago

US FDA rejects AstraZeneca's easier-to-use version of lupus therapy

AstraZeneca begins trading on the New York Stock Exchange

Feb 2, 2026, 7:00 AM EST - 1 day ago

AstraZeneca begins trading on the New York Stock Exchange

AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation

Feb 1, 2026, 2:49 AM EST - 2 days ago

AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation

AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC

Jan 30, 2026, 2:51 AM EST - 4 days ago

AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC

World leaders descend on Beijing as 2026 kicks off, hedging against U.S. disruptions

Jan 30, 2026, 2:15 AM EST - 4 days ago

World leaders descend on Beijing as 2026 kicks off, hedging against U.S. disruptions

China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy

Jan 29, 2026, 8:35 PM EST - 5 days ago

China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy

AstraZeneca sets out $15 billion China investment during Starmer visit

Jan 29, 2026, 5:00 AM EST - 5 days ago

AstraZeneca sets out $15 billion China investment during Starmer visit

University of Virginia Signs Master Research Collaboration Agreement with AstraZeneca to Accelerate Pre-Clinical Innovation

Jan 28, 2026, 4:01 PM EST - 6 days ago

University of Virginia Signs Master Research Collaboration Agreement with AstraZeneca to Accelerate Pre-Clinical Innovation

Airbus, AstraZeneca and HSBC executives join UK's Starmer on high-stakes China trip

Jan 27, 2026, 10:59 PM EST - 6 days ago

Airbus, AstraZeneca and HSBC executives join UK's Starmer on high-stakes China trip

HSBC

Astrazeneca CEO Soriot to join Starmer delegation to China, source says

Jan 26, 2026, 7:55 AM EST - 8 days ago

Astrazeneca CEO Soriot to join Starmer delegation to China, source says

AstraZeneca To Delist ADRs From Nasdaq By January, Eyes Broader Investor Reach

Jan 20, 2026, 11:47 AM EST - 14 days ago

AstraZeneca To Delist ADRs From Nasdaq By January, Eyes Broader Investor Reach

AstraZeneca to delist from Nasdaq, join NYSE in February

Jan 20, 2026, 2:21 AM EST - 14 days ago

AstraZeneca to delist from Nasdaq, join NYSE in February

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

Jan 15, 2026, 11:35 AM EST - 19 days ago

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

GEHC LLY RNA

AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 4:15 PM EST - 21 days ago

AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

AstraZeneca to acquire Modella AI to speed oncology drug research

Jan 13, 2026, 12:10 PM EST - 21 days ago

AstraZeneca to acquire Modella AI to speed oncology drug research

Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale

Jan 13, 2026, 12:02 PM EST - 21 days ago

Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale

AstraZeneca: Oncology Dominance Justifies New All-Time Highs

Jan 10, 2026, 10:00 AM EST - 24 days ago

AstraZeneca: Oncology Dominance Justifies New All-Time Highs

Healthy Returns: What to expect from pharma at the JPM conference

Jan 9, 2026, 12:57 PM EST - 25 days ago

Healthy Returns: What to expect from pharma at the JPM conference

AMGN BMY LLY MRK NVO PFE

AstraZeneca names Rick Suarez head of US biopharmaceuticals unit

Jan 8, 2026, 7:12 AM EST - 26 days ago

AstraZeneca names Rick Suarez head of US biopharmaceuticals unit

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

Jan 8, 2026, 7:00 AM EST - 26 days ago

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development

Jan 6, 2026, 7:44 AM EST - 4 weeks ago

BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development

These Healthcare and Bank Stocks Had Incredible Runs in 2025. Why Gains Will Continue This Year.

Jan 2, 2026, 1:55 PM EST - 4 weeks ago

These Healthcare and Bank Stocks Had Incredible Runs in 2025. Why Gains Will Continue This Year.

BK C CAH CVS

AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial

Dec 22, 2025, 2:39 AM EST - 6 weeks ago

AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial

AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial

Dec 22, 2025, 2:22 AM EST - 6 weeks ago

AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

Dec 19, 2025, 6:25 PM EST - 6 weeks ago

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

ALNY AMGN ARGX IBB

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 6 weeks ago

Trump to announce new drug-pricing deals later today

ABBV AMGN BMY GILD LLY MRK NVO

AstraZeneca: Mispriced Growth Following The Oncology Segment Success

Dec 19, 2025, 2:30 AM EST - 6 weeks ago

AstraZeneca: Mispriced Growth Following The Oncology Segment Success

AbbVie, several other pharma companies near MFN deal with Trump, sources say

Dec 17, 2025, 4:11 PM EST - 6 weeks ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AMGN BMY LLY NVS PFE

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

Dec 15, 2025, 4:29 PM EST - 7 weeks ago

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

AstraZeneca: A Rare Compound Growth Opportunity In Biopharma

Dec 10, 2025, 10:26 AM EST - 7 weeks ago

AstraZeneca: A Rare Compound Growth Opportunity In Biopharma

BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025

Dec 8, 2025, 8:10 AM EST - 2 months ago

BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025

Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement

Dec 4, 2025, 4:00 PM EST - 2 months ago

Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement

CRM

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Dec 4, 2025, 7:00 AM EST - 2 months ago

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

Dec 2, 2025, 9:18 AM EST - 2 months ago

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

BREAKING: Trump strikes major deal with UK on drug pricing

Dec 1, 2025, 10:15 AM EST - 2 months ago

BREAKING: Trump strikes major deal with UK on drug pricing

EWU EWUS FKU FLGB FXB GSK

Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies

Nov 26, 2025, 12:18 PM EST - 2 months ago

Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies

NVO

AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows

Nov 24, 2025, 12:58 PM EST - 2 months ago

AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

Nov 23, 2025, 7:01 PM EST - 2 months ago

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer

Nov 21, 2025, 8:22 PM EST - 2 months ago

AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer

AstraZeneca to invest $2 billion as part of US manufacturing push

Nov 21, 2025, 2:05 PM EST - 2 months ago

AstraZeneca to invest $2 billion as part of US manufacturing push

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

Nov 21, 2025, 2:05 PM EST - 2 months ago

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Nov 18, 2025, 4:21 PM EST - 2 months ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

JNJ LLY MDT MRK NVO OLMA PFE

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 2 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN BIIB GILD GSK JNJ LLY

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Nov 14, 2025, 3:19 PM EST - 2 months ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

ABBV JNJ LLY MRK NVO PFE XLV

Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes

Nov 14, 2025, 7:06 AM EST - 2 months ago

Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes

LLY

FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines

Nov 11, 2025, 7:45 AM EST - 3 months ago

FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines

AstraZeneca hits record high, cements lead as UK's biggest stock

Nov 11, 2025, 3:42 AM EST - 3 months ago

AstraZeneca hits record high, cements lead as UK's biggest stock

AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial

Nov 10, 2025, 1:39 PM EST - 3 months ago

AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

Nov 9, 2025, 4:33 PM EST - 3 months ago

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

Quantumup
Quantumup Feb. 3 at 7:23 PM
BofA⬆️ $BBIO's PT to $88 from $85 and reiterated at a Buy after providing its thoughts ahead of 4Q earnings. $ALNY $PFE NVO $AZN - IONS $BAYRY Here's what BofA had to say in its note: https://x.com/Quantumup1/status/2018766232087130238?s=20
0 · Reply
TalkMarkets
TalkMarkets Feb. 3 at 5:34 PM
The #FTSE100 Finish Line - Tuesday, Feb. 3 $EWU $AZN https://talkmarkets.com/content/global-markets/the-ftse-100-finish-line-tuesday-feb-3?post=554705
0 · Reply
Auphiliate
Auphiliate Feb. 3 at 4:29 PM
$AUPH Also added $AZN to my watchlist! 🤷‍♀️
0 · Reply
Chipwars
Chipwars Feb. 3 at 2:39 PM
$AZN NYSE-listed AstraZeneca scored a winning debut on the NYSE during Monday's session, climbing 0.7%. The firm began trading on the exchange, marking the largest company transfer by market capitalization in NYSE history. https://finance.yahoo.com/news/nyse-content-advisory-pre-market-135500825.html
0 · Reply
Chipwars
Chipwars Feb. 3 at 1:45 PM
$AZN This is excellent news. A priority review means that the drug WORKS, for breast cancer, and is rushed through to stop people dying. Great news for those patients as well as for Astrazeneca stock. https://in.investing.com/news/company-news/fda-grants-priority-review-to-astrazenecas-breast-cancer-drug-datroway-93CH-5218086
0 · Reply
IndependentIntelInt
IndependentIntelInt Feb. 3 at 1:21 PM
$EOSE $AZN Clean and pharma
0 · Reply
briefingcom
briefingcom Feb. 3 at 1:16 PM
$AZN: AstraZeneca updates on U.S. regulatory review of Saphnelo subcutaneous formulation https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260203051146AZN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
Chipwars
Chipwars Feb. 3 at 11:22 AM
$AZN https://finance.yahoo.com/news/astrazeneca-plc-nasdaq-azn-announces-093429467.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAALU3JVjKj7DzNa5xvaKMAewwX7VbIHPv_UieB1kq1zKD17BLIwkmM18QDhH7dpt3T5btYP9xcp2lO-q9KVk7eBpbD8yxnNa9_EXA_j4CGYUUKwWK3mCfVAw2kqmLWjhKUilZNxkFu8Olbb-Uqc2-ba9UjfQUdliWNxchDZJoR8hY
0 · Reply
Pevzner_Maestro
Pevzner_Maestro Feb. 3 at 9:13 AM
$AZN I’m thinking of entering short
1 · Reply
chazthespaz
chazthespaz Feb. 3 at 5:50 AM
$NVAX yall see $AZN astra zeneca? Maybe theres some synergy there. Maybe we will spike to $100 by next week 🤷
0 · Reply
MichaelBurns978
MichaelBurns978 Feb. 3 at 5:27 AM
$HSBC $AZN International exposure
0 · Reply
resq1
resq1 Feb. 3 at 2:48 AM
$AZN Distraction of the failed projections of their pricey Alexion acquisition.
1 · Reply
topstockalerts
topstockalerts Feb. 3 at 1:39 AM
Top Gainers $DKI $AZN $FUSE $RPGL $SORA
0 · Reply
topstockalerts
topstockalerts Feb. 2 at 11:42 PM
Top Gainers $DKI $AZN $FUSE $RPGL $SORA
0 · Reply
topstockalerts
topstockalerts Feb. 2 at 9:53 PM
Top Gainers $DKI $AZN $FUSE $RPGL $SORA
0 · Reply
topstockalerts
topstockalerts Feb. 2 at 9:09 PM
$AZN higher tonight?
0 · Reply
topstockalerts
topstockalerts Feb. 2 at 8:59 PM
Top Gainers $DKI $SORA $AZN $FUSE $XTKG
0 · Reply
topstockalerts
topstockalerts Feb. 2 at 7:53 PM
Top Gainers $JLHL $DKI $AZN $PBM $FUSE
0 · Reply
Nycteo
Nycteo Feb. 2 at 7:43 PM
$FUSE look these top gainers today guys, FUSE is the most serious stock, put your money here and leave trash $PBM $DKI $AZN
0 · Reply
TradeSun
TradeSun Feb. 2 at 6:38 PM
$ALT $XBI $AZN $LLY $NVO I´m already working on my potential post-Altimmune investments... after a hopefully but imo expectable big move. This is a list with STRONG BUY-rated stocks only with a MCap between $ 0.2 - 2.68 B. Any recommendations?
5 · Reply
topstockalerts
topstockalerts Feb. 2 at 6:28 PM
$AZN This one was on watch and now it’s moving 👀. Buyers stepped in right on time. That’s how breakouts start.
0 · Reply
char13
char13 Feb. 2 at 6:09 PM
$AZN this was maasive today, congrats
0 · Reply